Xconomy's Luke Timmerman spent some time with the CEO and CBO at Epizyme to see how the three-year-old biotech was able to score two impressive development deals with Big Pharma earlier this year.
Epizyme has been making a reputation for itself in the hot field of epigenetics, which promises to find the right approach to turning off enzymes that play a key role in cancer. CBO Jason Rhodes notes that one of the big attractions for Big Pharma has been the potential to develop small molecules that can bind very specifically to the 3-D structures.
"These genes are really part of an orchestra," says Rhodes. "We can influence the entire orchestra." But it's still early days in the life of Epizyme, which is still a couple of years away from the clinic.
- read the article from Xconomy